Metagenomi Therapeutics, Inc. Increase (Decrease) in Accounts Receivable
Metagenomi Therapeutics, Inc. (MGX) reported Increase (Decrease) in Accounts Receivable of -$305.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-10
- Metagenomi Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $0.00.
- Metagenomi Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$305.00K.
- Metagenomi Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$655.00K, a 198.05% decline year-over-year.
- Metagenomi Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $87.00K.
- Metagenomi Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2025 was -$952.00K.
- Metagenomi Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2024 was -$1.19M, a 148.71% decline from fiscal 2023.
- Metagenomi Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2023 was $2.45M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$305.00K 10-Q · filed 2026-08-10 | -$960.00K derived: sum of 3 quarters · filed 2026-08-10 | -$873.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$305.00K 10-Q · filed 2026-05-11 | -$960.00K derived: sum of 2 quarters · filed 2026-05-11 | -$873.00K derived: sum of 3 quarters · filed 2026-05-11 | -$1.01M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$655.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$568.00K derived: sum of 2 quarters · filed 2026-03-05 | -$707.00K derived: sum of 3 quarters · filed 2026-08-10 | -$952.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $87.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$52.00K derived: sum of 2 quarters · filed 2026-08-10 | -$297.00K 10-Q · filed 2025-11-12 | $371.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$139.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$384.00K 10-Q · filed 2026-08-10 | $284.00K derived: sum of 3 quarters · filed 2026-08-10 | -$775.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$245.00K 10-Q · filed 2026-05-11 | $423.00K derived: sum of 2 quarters · filed 2026-05-11 | -$636.00K derived: sum of 3 quarters · filed 2026-05-11 | -$1.07M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $668.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$391.00K derived: sum of 2 quarters · filed 2026-03-05 | -$825.00K derived: sum of 3 quarters · filed 2026-03-05 | -$1.19M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.49M derived: sum of 2 quarters · filed 2025-11-12 | -$1.86M 10-Q · filed 2025-11-12 | -$3.33M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$434.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$803.00K 10-Q · filed 2025-08-12 | -$2.28M derived: sum of 3 quarters · filed 2025-08-12 | -$680.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$369.00K 10-Q · filed 2025-05-13 | -$1.84M derived: sum of 2 quarters · filed 2025-05-13 | -$246.00K derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | -$1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $123.00K derived: sum of 2 quarters · filed 2025-03-17 | $2.45M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $3.92M 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $2.33M 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |